

Electronic Acknowledgement Receipt

EFS ID:	9060822
Application Number:	09451641
International Application Number:	
Confirmation Number:	9327
Title of Invention:	CELECOXIB COMPOSITIONS
First Named Inventor/Applicant Name:	Danchen Gao
Customer Number:	28523
Filer:	Arthur Dean Olson/Kelly Smith
Filer Authorized By:	Arthur Dean Olson
Attorney Docket Number:	PC10664
Receipt Date:	17-DEC-2010
Filing Date:	30-NOV-1999
Time Stamp:	12:44:00
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$ 180
RAM confirmation Number	11884
Deposit Account	161445
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

File Listing:					
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Transmittal Letter	PC10664A-Supplemental_IDS.pdf	31915	no	1
			d1a9d33af098cddd35c91b08529433f5934d5b1d		
Warnings:					
Information:					
2	Information Disclosure Statement (IDS) Filed (SB/08)	PC10664A-Supplemental_IDS_Citation.pdf	145007	no	4
			68a1f4f715531be06219caa4f25dffbb6f2abb14		
Warnings:					
Information:					
This is not an USPTO supplied IDS fillable form					
3	Foreign Reference	EP0488856B1.pdf	5611769	no	23
			8e032efe13d83659cfc744b0c968b26130a803df		
Warnings:					
Information:					
4	Foreign Reference	WO0048583.pdf	1291708	no	7
			4147944f4b3e2d11731240ff0fe6ffd946814dbd		
Warnings:					
Information:					
5	NPL Documents	Nature-367-215-216.pdf	1096799	no	2
			8e9ebb51d5a83da9b4218612bac5058e395a9fc1		
Warnings:					
Information:					
6	NPL Documents	Drug_News_and_Perspectives-7_501-512.pdf	4606782	no	12
			e59073ecac52f088dd3863c2c952f128976dbac7		
Warnings:					
Information:					
7	NPL Documents	Tucker_Declaration.pdf	3399300	no	21
			04a42547d1e7771b469e8c15e53cea13d03821c4		
Warnings:					
Information:					
8	NPL Documents	Rompp_Cemi_Lexikon.pdf	1373231	no	4
			bf350a3f6cc1b6b534d0d824e575b84b86aa828a		
Warnings:					
Information:					

9	NPL Documents	J_Pharm_Pharmaceut_Sci-6_205-210.pdf	1630583	no	6
			9c5c76a4d12cd0f1378ba3b7bccb44bae080019c		
Warnings:					
Information:					
10	NPL Documents	Pharmaceutical_Research-21_201-230.pdf	9075973	no	30
			b7b6321fcfd5cafadf32ea3fe68ac90466ed289		
Warnings:					
Information:					
11	NPL Documents	Drug_Bioavailability_207-209.pdf	589625	no	3
			e47b795008df871d8e31a9e8c8d949ff66ed1445		
Warnings:					
Information:					
12	NPL Documents	Clin_Pharmacokinet-39_225-242.pdf	5105105	no	18
			731ab0e17720ae73df1b1d1f728f4f69a3a2c02		
Warnings:					
Information:					
13	NPL Documents	Barnett_International.pdf	2877173	no	6
			2d1458617ac32322b89aaa0e621dcd35cc7431f5		
Warnings:					
Information:					
14	NPL Documents	PSG_Technical_Conference.pdf	1777542	no	8
			c8fbf622c060adf9b15bcdcbad6df7b9f0e42d5e		
Warnings:					
Information:					
15	NPL Documents	Experimental_Protocol.pdf	744598	no	5
			3cabafc6702cb84be971854f6ed0cf3fea02cd779		
Warnings:					
Information:					
16	NPL Documents	Exp_Opin_Pharmacotherapy-2_139-152.pdf	4775055	no	14
			304c7a840eb9b22ad51d3fb250784ce98cca9b6e		
Warnings:					
Information:					
17	NPL Documents	Davies_Declaration.pdf	3080285	no	18
			d07b826f3b52e8722e4d52fa133c9b4efdd517f4		
Warnings:					
Information:					

18	NPL Documents	Taskin_Declaration.pdf	619640	no	3
			6509391c4d78ee2e688675748013155b689ca358		
Warnings:					
Information:					
19	NPL Documents	Kesten.pdf	3275983	no	20
			654dc4081b3867d63d61a3e1d4f7fc90d62b359		
Warnings:					
Information:					
20	NPL Documents	Clinical_Trial_Protocol_N49-95-02-006.pdf	15394113	no	87
			321fccbe8268e1a286283677b2efe7d74f166579		
Warnings:					
Information:					
21	NPL Documents	Internal_Pfizer_Document.pdf	1128358	no	8
			5d544b6bc60228c4d747f93cef18a31796aa63a9		
Warnings:					
Information:					
22	NPL Documents	Consultant_Agreement.pdf	1253119	no	6
			27269f5f5bf2dc8f7791768d48be53515d9f90e5		
Warnings:					
Information:					
23	NPL Documents	Pharm_Development_and_Technology-3_153-161.pdf	1823871	no	9
			7e195cc2ea79869076e7f0340cfae8c481a54df8		
Warnings:					
Information:					
24	NPL Documents	Pharmaceutical_Dosage_Forms_Vol2.pdf	728026	no	4
			04a16da89998afd14d3a31a503fd98bea45bf2bc		
Warnings:					
Information:					
25	NPL Documents	Proc_R_Soc_Lond-419-137-149.pdf	2585126	no	13
			fe9845ba3606e3e0673d3e490b97c300b9c4d6e5		
Warnings:					
Information:					
26	NPL Documents	Benita_affidavit_1_Israel_opposition.pdf	2555284	no	10
			d6756bd1f5c42cb41c9b85af5b964f13cb33c22e		
Warnings:					
Information:					

27	NPL Documents	Benita_affidavit_2.pdf	24538680	no	73
			30017a1a6f8349cb4833c3c60bdf45a58a6749c8		
Warnings:					
Information:					
28	NPL Documents	bolivia_opposition.pdf	765883	no	3
			ea2dd2e74df8845f0fb37db4ada7d60c141a1ea9		
Warnings:					
Information:					
29	NPL Documents	Colombia_rejection.pdf	1976175	no	10
			d27f4b125b75c2a86a482e4c509d22852b5c0098		
Warnings:					
Information:					
30	NPL Documents	Costa_Rica_rejection_overcome_later.pdf	1080257	no	16
			a43e13458db194c07a2387d5440820cfdc1be8a5		
Warnings:					
Information:					
31	NPL Documents	Cynthia_Webb-Israel-affidavit1.pdf	2430592	no	10
			2ec85d0d4dceb1fd7e0af2c52c8deac2983b0eaa		
Warnings:					
Information:					
32	NPL Documents	Danon_affidavit1_Israel_opposition.pdf	2605383	no	8
			33e6e1973e85d043a7f782b0361518eae5c4b95d		
Warnings:					
Information:					
33	NPL Documents	Danon_affidavit2_Israel-Opposition.pdf	18580301	no	57
			330548cccf5377dc2be617eafdba22bafae1c42		
Warnings:					
Information:					
34	NPL Documents	Ecuador_opposition.pdf	1358692	no	5
			9707f25d70aa13d5a725275dd2303335738e72ab		
Warnings:					
Information:					
35	Foreign Reference	EPO_Appeal_decision.pdf	9734667	no	58
			cba49672e8356f918719b69fe6175da6da5b56f6		
Warnings:					
Information:					

36	NPL Documents	EPO_Opposition_decision.pdf	5399494	no	27
			0a1747e7fe77781de3a5764c6825619d2916c5b9		
Warnings:					
Information:					
37	NPL Documents	EPO_oppositions.pdf	10952421	no	60
			9f1cfd3f32d9a855663bd5c9645e0cbc7daf1aff		
Warnings:					
Information:					
38	NPL Documents	Estonia_Opposition.pdf	3858837	no	12
			00a4388a43b7d5a25da0e1d3304ba83440a48819		
Warnings:					
Information:					
39	NPL Documents	Eurasian_opposition.pdf	2217576	no	9
			5ba9fdc47a4dfed0e9b31eab3146efc0fc5aa7e9		
Warnings:					
Information:					
40	NPL Documents	Davies_AffidavitandReferences-Guatemala.pdf	14634100	no	123
			873f9a47cdf177843c5a709ccc620b095db23d7		
Warnings:					
The page size in the PDF is too large. The pages should be 8.5 x 11 or A4. If this PDF is submitted, the pages will be resized upon entry into the Image File Wrapper and may affect subsequent processing					
Information:					
41	NPL Documents	Guatemala-Final_Decision.pdf	3211249	no	14
			d703303205470b36b4e24131bc9998b652945bd9		
Warnings:					
Information:					
42	NPL Documents	Guatemala-Rejection-June_2003.pdf	472457	no	2
			75566189fb6cf0b89991920e42e8e858c3082025		
Warnings:					
Information:					
43	NPL Documents	Guatemala-Response_To_Examiner_Rejection.pdf	1977626	no	6
			7889c98455c0c5b291a9b15137c34178cc9791b8		
Warnings:					
Information:					
44	NPL Documents	Guatemala_Submission-April_2004.pdf	5337623	no	31
			4eb9eb5d34202c1bd978a2771f9f6188a1ddb15		

Warnings:					
Information:					
45	NPL Documents	Isreal_Opposition_Summations.pdf	8139866	no	55
			823e245ebd991f270b20c86ed521ae4da31722a8		
Warnings:					
Information:					
46	NPL Documents	Opposition_Decision-Isreal.pdf	7159991	no	26
			f6f81afb1e309e8f6b1d81b2393332df322adee6		
Warnings:					
Information:					
47	NPL Documents	Philippines-Set_Aside_Refusal.pdf	17773917	no	67
			3b7e7e8245814eb4b091073d2c710941b396fa34		
Warnings:					
Information:					
48	NPL Documents	Israel-Notice_of_Appeal.pdf	9257696	no	44
			8cb41219de21c814d62c390b7e024e3fe39a18b5		
Warnings:					
Information:					
49	NPL Documents	Davies_declaration-Israel_Opposition.pdf	4366306	no	28
			b4443f94746ae7b6c822ecbe99d83ad55795781b		
Warnings:					
Information:					
50	NPL Documents	Venezuela-Response.pdf	2630191	no	9
			3c90e352046bec84c7065a55c92bbc1d9b25c6ce		
Warnings:					
Information:					
51	NPL Documents	Peru-Annulment_Action.pdf	10523456	no	37
			eab76501f29bb1167f5fc5700444cd4d72b0ce13		
Warnings:					
Information:					
52	NPL Documents	Polpharma_Appeal-Poland.pdf	1695156	no	8
			1749b626df53cbcee48cbc7aeec5a563fc901ad9		
Warnings:					
Information:					
53	NPL Documents	Zentiva-Appeal-Poland.pdf	3654677	no	16
			9d3fa966f3010b5f3514f178aae5aaef00093b33		

Warnings:					
Information:					
54	NPL Documents	Slovak-decision.pdf	6795685	no	22
			3c44c28db6ffc3bc51f01e9a3b01a76fd5301d16		
Warnings:					
Information:					
55	NPL Documents	Slovak-Nullity_action.pdf	2816708	no	12
			2bddb98cc9bfdd20527e791ddad5f3af8b353ae7		
Warnings:					
Information:					
56	NPL Documents	Teva-Opposition_Arguments-Isreal.pdf	936338	no	6
			58fdcecb290eef334754a2178010796434f6f56		
Warnings:					
Information:					
57	NPL Documents	Turkish_Opposition-Fako.pdf	243729	no	2
			7e9b69514eb1098daa3b67c254d23436563ffa05		
Warnings:					
Information:					
58	NPL Documents	Turkish_Opposition-Oner.pdf	257323	no	2
			1184d412131053d650ff28e9c1698c176be66737		
Warnings:					
Information:					
59	NPL Documents	Turkish_Opposition-Tum.pdf	667335	no	3
			1cb547ff8d57b63de5abec007db5c8ba5e3d4c2d		
Warnings:					
Information:					
60	NPL Documents	Turkish_Opposition-Nobel_Ilac.pdf	701890	no	4
			262d0d587f6cd9c22a6f5eb0c57038455856311a		
Warnings:					
Information:					
61	Fee Worksheet (PTO-875)	fee-info.pdf	30224	no	2
			d9aa13d628b0d61d4d69e0bb028c75aec2976128		
Warnings:					
Information:					
Total Files Size (in bytes):			265358471		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.